OU Portal
Log In
Welcome
Applicants
Z6_60GI02O0O8IDC0QEJUJ26TJDI4
>
Publ3 search
Error:
Javascript is disabled in this browser. This page requires Javascript. Modify your browser's settings to allow Javascript to execute. See your browser's documentation for specific instructions.
{}
Close
Publikační činnost
Probíhá načítání, čekejte prosím...
publicationId :
tempRecordId :
actionDispatchIndex :
navigationBranch :
pageMode :
tabSelected :
isRivValid :
Record type:
stať ve sborníku (D)
Home Department:
Katedra interních oborů (11300)
Title:
Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial
Citace
Jacobsen, E., Ardeshna, K., Cherry, M., Offner, F., Majer, J., Bijou, F., Monica, T., Ďuraš, J., Musuraca, G., Merli, M., Marasca, R., Weaver, D., Lustgarten, S., Youssoufian, H. a Zinzani, P. L. Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial.
In:
2019 Society of Hematologic Oncology (SOHO) Annual Meeting: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019-09-11 Houston, Texas.
s. 312-312. ISSN 2152-2650.
Subtitle
Publication year:
2019
Obor:
Onkologie a hematologie
Number of pages:
1
Page from:
312
Page to:
312
Form of publication:
Tištená verze
ISBN code:
neuvedeno
ISSN code:
2152-2650
Proceedings title:
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Proceedings:
Mezinárodní
Publisher name:
neuvedeno
Place of publishing:
Dallas, USA
Country of Publication:
Sborník vydaný v zahraničí
Název konference:
2019 Society of Hematologic Oncology (SOHO) Annual Meeting
Místo konání konference:
Houston, Texas
Datum zahájení konference:
Typ akce podle státní
příslušnosti účastníků:
Celosvětová akce
WoS code:
000483480700318
EID:
Key words in English:
marginal zone lymphoma, PI3K, duvelisib, IBCL, indolent B-cell lymphoma
Annotation in original language:
Duvelisib, a first-in-class oral dual PI3-kinase-δ,γ inhibitor, is approved for the treatment of R/R CLL/SLL after ≥2 prior therapies and for follicular lymphoma (FL) after ≥2 prior systemic therapies. DYNAMO, a phase 2 trial that evaluated the safety and efficacy of duvelisib monotherapy in iNHL, including patients with marginal zone lymphoma (MZL). Patients were double refractory to rituximab-based therapy and chemotherapy or radioimmunotherapy.
Annotation in english language:
References
Reference
R01:
RIV/61988987:17110/19:A21025QH
Complementary Content
Deferred Modules
${title}
${badge}
${loading}
Deferred Modules
Probíhá načítání, čekejte prosím...